About the Company
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CALA News
Calithera Biosciences, Inc. (CALA)
May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the ...
Coinbase Cost Cuts, Netflix Earnings And Factor Investing: Forbes AI Newsletter - July 23rd
Calithera Biosciences Inc (CALA) – The biopharmaceutical business is a Top Short for next month and our AI rates it as an F in Quality Value and a D in Low Momentum Volatility. Net income was -$ ...
ALX Oncology Appoints Allison Dillon as Chief Business Officer
May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company ... Dr. Dillon joined ALX Oncology from Calithera Biosciences, where she most recently served as Senior ...
Pacira BioSciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
TAKEDA PHARMACEUTICAL CO LTD's Net Worth
Who is TAKEDA PHARMACEUTICAL CO LTD? TAKEDA PHARMACEUTICAL CO LTD has an estimated net worth of $461 Million. This is based on reported shares across multiple companies, which include Calithera ...
Coherus BioSciences: Q1 Earnings Snapshot
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus BioSciences Inc. (CHRS) on Thursday reported earnings of $102.9 million in its first quarter. On a per-share basis, the Redwood City, ...
CHRS Coherus BioSciences, Inc.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops ...
IGMS IGM Biosciences, Inc.
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops ...
Anixa Biosciences, Inc.
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following ...
Calithera Biosciences, Inc. (CALA)
May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the “Special ...
Calithera Biosciences, Inc. (CALA)
May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the “Special ...
Calithera Biosciences, Inc. (CALA)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...